CLEC-16A Antibodies

Santa Cruz Biotechnology offers a broad range of CLEC-16A monoclonal antibodies for research focused on understanding immune response regulation. CLEC-16A monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CLEC-16A, a C-type lectin domain family member, plays a crucial role in immune response regulation and shows significant associations with autoimmune diseases, particularly multiple sclerosis. Research has demonstrated CLEC-16A's involvement in antigen recognition and immune cell activity modulation, emphasizing its importance in both normal physiological functions and disease states. Investigating CLEC-16A's molecular mechanisms continues to reveal potential therapeutic targets for autoimmune conditions. Current studies focus on understanding how CLEC-16A influences immune cell development and function. Ongoing research explores CLEC-16A's role in cellular signaling pathways and its impact on immune system regulation. CLEC-16A monoclonal antibodies from Santa Cruz Biotechnology enable researchers worldwide to advance scientific understanding of autoimmune diseases and potential therapeutic interventions.